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DOI 10.1016/j.immuni.2009.03.008The article by Hill et al. (2008), published in
the November 14, 2008 issue of Immunity,
describes a mechanism by which retinoic
acid (RA) enhances TGF-b-induced Foxp3
expression. The authors propose that RA
does not act directly on naive T cells during
activation in culture but rather indirectly via
negative regulation of an accompanying
population of effector or memory CD4+
CD44hi cells. They reasoned that the
increased generation of Foxp3+ cells in
response to RA in culture, as described
previously (Coombes et al., 2007; Elias
et al., 2008; Mucida et al., 2007; Sun
et al., 2007; Xiao et al., 2008), represented
the lifting by RA of inhibition imparted by
accompanying CD4+CD44hi T cells, rather
than by direct or indirect effects of RA on
the Foxp3 expression of the primed naive
T cells themselves.
In order to assess the effects of RA
on naive T cells in the absence of ac-
companying CD4+CD44hi T cells, we
sorted (CD4+CD25CD44lo CD62L+) GFP
T cells (more than 99.7% purity) from
Foxp3-eGFP reporter mice (Figure S1A
available online) by flow cytometry. After
4 days of stimulation with anti-CD3 and
anti-CD28, we stained CD4 cells with
7AAD to exclude dead cells; additionally,
forward and side scatter (area versus
width) was used to exclude doublets,
and we evaluated Foxp3 expression via
GFP staining. Addition of RA enhanced
Foxp3 induction more than 50% by use
of 1 or 10 ng/ml doses of TGF-b (Fig-
ure S1B). Because the sorting efficiency
is not 100%, it is possible that extremely
low numbers of ‘‘accompanying’’ memory
or effector cells could still influence these
results. To exclude this possibility, we
used FACS-sorted CD4+CD25CD44lo
CD62L+ T cells, isolated from B7-1 and
B7-2 double-deficient mice (Cd80/
Cd86/), which even before sorting
already contain less than 5% of memory
or effector CD44hi cells (data not shown).RA also greatly enhanced Foxp3 induced
by TGF-b in CD4+CD25CD44lo CD62L+
naive T cells isolated from Cd80/
Cd86/ mice (Figure S1C). Moreover,
we showed previously that RA is able to
counterbalance the inhibitory effects of
costimulation on TGF-b-mediated Foxp3
induction, with either CD4+CD25 or
CD4+Foxp3 T cells (Benson et al.,
2007). To confirm these results, we used
OTII TCR transgenic CD4+CD25CD44lo
CD62L+ cells sorted by flow cytometry
and tested the effects of RA by using
increasing doses of anti-CD28 stimula-
tion. We found that RA markedly
enhanced TGF-b-mediated Foxp3 induc-
tion on pure naive CD4+ T cells that were
stimulated with anti-CD3 and various
doses of anti-CD28 (Figure S1D). The
enhanced Foxp3 expression mediated
byRA ismorepronouncedonnaivemono-
clonal OTII TCR transgenic T cells as
compared to polyclonal T cells, consistent
with a lesser frequency of ‘‘contami-
nating’’ memory T cells.
Finally, because we showed previously
that RA-mediated enhanced expression
of Foxp3 is greatly reduced in the absence
of IL-2 (Mucida et al., 2007), we investi-
gated the effects of RA on naive T cells
with various doses of exogenous IL-2.
Although IL-2-deficient mice develop
inflammatory disorders, Il2/Cd80/
Cd86/ mice are healthy and, more
importantly, they do not contain T regula-
tory cells. At steady state, 99% of all
CD4+ T cells isolated from Il2/Cd80/
Cd86/ mice are naive (data not shown).
The CD4+ T cells were further sorted by
flow cytometry so that highly purified naive
CD4+CD25CD44lo CD62L+ cells (more
than 99.9% purity) were obtained. The
sorted naive CD4+ Il2/Cd80/Cd86/
T cells were tested for TGF-b-induced
Foxp3 expression in the presence of
increasing doses of IL-2 and anti-CD3
and anti-CD28 coated beads, with orImmunitwithout RA. The data showed that 1 nM
RA distinctly enhanced TGF-b (1 ng/ml)-
mediated Foxp3 induction in pure naive
CD4+ T cells at all doses of IL-2 examined
(Figures S1E and S1F). Strikingly, although
the expression of Foxp3 was much
reduced, RA enhanced TGF-b-mediated
Foxp3 induction not only in the absence
of memory or effector T cells but also in
the absence of IL-2.
These data demonstrate that RA medi-
ates enhanced TGF-b-induced Foxp3
expression upon activation of pure naive
T cells in the absence of accompanying
CD4+CD44hi T cells. In addition, we
confirmed, as Hill et al. (2008) proposed,
that RA also efficiently counteracts inhibi-
tory effects of CD44hi T cells on Foxp3
induction (data not shown), which indi-
cates that RA is able to enhance Foxp3
expression both, via effects directly on
the primed naive T cells as well as indi-
rectly via inhibitory effects on accompa-
nying CD4+CD44hi T cells.
There is no doubt that the new findings
by Hill et al. (2008) add an important new
pathway by which RA can enhance Foxp3
induction, which had been suggested
previously (Elias et al., 2008; Mucida
etal., 2007;Xiaoetal., 2008).Nevertheless,
published data, together with the data pre-
sented here, disagree with the central
statement proposed by Hill et al. (2008)
that the enhanced expression of TGF-b
driven Foxp3mediated byRA is an indirect
effect that requires suppression of accom-
panyingCD4+CD44hi T cells rather than via
direct or indirect effects on the primed
T cells themselves. Under physiological
conditions, naive T cells may be exposed
to cytokines and effector or memory cells,
and hence it is likely that during priming
of naive T cells, both mechanisms of RA-
mediated enhanced TGF-b driven Foxp3
expression in the primed T cells will syner-
gize in vivo. Therefore, elucidating and
understanding both processes by whichy 30, April 17, 2009 ª2009 Elsevier Inc. 471
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T cells is important and may lead to the
identification of possible targets for thera-
peutic interventions to treat various inflam-
matory and autoimmune diseases.
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We thank our colleagues for their interest
in our recent paper, which showed that
retinoic acid (RA), binding to the RARa
receptor, influences TGFb-induced Foxp3
expression through an indirect manner,
either by repressing IL-6Ra or by damp-
ening theproductionof inhibitory cytokines
(IFN-g, IL-4, and IL-21). Thesourceof these
cytokines, in our culture conditions, was
CD44hi memory and/or effector phenotype
CD4+ T cells. Several other papers have
appeared on the topic, investigating the
responsiveness of isolated naive cells to
RA, a question of importance in under-
standing the molecular mechanisms that
link RA to FoxP3 expression. This letter
offers us the possibility to clarify the issue.
RA could influence FoxP3 induction
through several, nonmutually exclusive,
mechanisms. First, an immediate and
‘‘direct’’ effect leading to activation of
the FoxP3 locus, acting in naive T cells
independently of any other influence
(e.g., by direct transactivation of the
Foxp3 locus or by potentiation of TGF-b
signaling). Second, RA can inhibit the
expression of the IL-6 receptor, thus
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dampening the sensitivity to the inhibitory
effect of this cytokine; this mechanism
has been demonstrated by Xiao et al.
and ourselves (Xiao et al., 2008; Hill
et al., 2008). Third, RA can shut down
the synthesis of cytokines (IFN-g, IL-4,
and IL-21), which in concert have an inhib-
itory effect on FoxP3 induction. This is the
mechanism shown in our previous paper
(Hill et al., 2008), by microarray analysis
demonstrating a wholesale shutdown of
cytokine genes by RA, consistent with
other reports (Elias et al., 2008; Takaki
et al., 2008; Maynard et al., 2009).
At issue, then, is whether RA can affect
FoxP3 expression in isolated naive T cells,
independent of other cytokines or other
cellular influences. Experimental condi-
tions in which naive T cells are stimulated
in the presence of IL-6, of dendritic cells,
or of other antigen-presenting cells do not
address the point because they may read
out mechanism #2 (e.g., experiments in
Maynard et al. [2009] and Mucida et al.
[2007]). Some reports have shown direct
responses of carefully isolated naive
T cells (Xiao et al., 2008; Elias et al., 2008;
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and Figure S1 from the letter of Mucida
et al., 2009). Yet, these inductions are
carried out in conditions of T cell activation
that can readily lead to effector cell dif-
ferentiation, and thus to IFN-g, IL-4, and
IL-21 production (over 4 days’ culture).
Indeed, cytokine-mediated inhibition of
FoxP3 expression may well be at play in
some of these ‘‘naive responder’’ experi-
ments. The progressive inhibition of FoxP3
induction with increasing doses of anti-
CD28, and its reversal by RA (Figure S1
in Mucida et al., 2009), can plausibly be
interpreted as cytokine production that
increases with costimulatory signals. In
the report of Xiao et al. (Xiao et al., 2008),
RA treatment leads to increased Smad3
phosphorylation, and a known effect of
IFN-g signaling is the inhibition of Smad3
phosphorylation (Ulloa et al., 1999).
Thus, although the direct effects of
mechanism #1 remain a possibility (and
one suggested by the existence of an
RAR-responsive element in the body of
Foxp3 [Takaki et al., 2008]), the interplay
between RA and inhibitory cytokines
mean that any claim that FoxP3 induction
